登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>4-1BB & CD32b >CK-007

Cell-based Screening Kit for Anti-human 4-1BB Antibody (Human CD32b Low Expression)

For research use only.

IDComponentsSize
CHEK-ATF073Human 4-1BB (Luc) HEK293 Reporter Cell2 Vials
SCCHO-ATP060LCHO/Human CD32b Stable Cell Line (Low Expression) Development Service2 Vials

描述(Description)

The Cell-based Kit consists of two engineered cell lines, Human 4-1BB (Luc) HEK293 Reporter Cell (Cat.No.CHEK-ATF073) and CHO/Human CD32b Stable Cell Line (Low Expression) (Cat.No.SCCHO-ATP060L). The Human 4-1BB (Luc) HEK293 Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human 4-1BB (Gene ID: 3604), which can drive luciferase expressing systems by 4-1BB ligand/ agonist antibody stimulation. The CHO/Human CD32b Stable Cell Line was engineered to express full length human CD32b receptor (Gene ID: 2213), with different levels of CD32b expression (High, Medium, Low), which can be used to test agonist antibody whether in a CD32b-dependent manner to strengthen the agonistic activity. When co-cultured with Human 4-1BB (Luc) HEK293 Reporter Cell and anti-4-1BB agonist antibody, the anti-4-1BB antibody can be crosslinked, thereby strengthening 4-1BB pathway-activated luminescence.

应用说明(Application)

• Screen for Anti-human 4-1BB antibodies whether in a CD32b-dependent manner to strengthen the agonistic activity

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

4-1BB & CD32b FACS

Expression analysis of human 4-1BB on Human 4-1BB (Luc) HEK293 Reporter Cell by FACS.
Cell surface staining was performed on Human 4-1BB (Luc) HEK293 Reporter Cell or negative control cell using PE-labeled anti-human 4-1BB antibody.

Protocol

4-1BB & CD32b FACS

Expression analysis of human CD32b on CHO/Human CD32b Stable Cell Line by FACS.
Cell surface staining using PE/Cy7-labeled anti-human CD32b antibody was performed on CHO/Human CD32b Stable Cell Line with different expression levels: CHO/Human CD32b Stable Cell Line (Low Expression); CHO/Human CD32b Stable Cell Line (Medium Expression); CHO/Human CD32b Stable Cell Line (High Expression).

Protocol

 

背景(Background)

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

 

License Disclosure

This cell line is provided for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit modification of this cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license. Modifications of this cell line, transfer to another facility, or commercial use of the cell lines may require a separate license and additional fees. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定